Royalty Pharma PLC $RPRX is Torray Investment Partners LLC’s 3rd Largest Position

Torray Investment Partners LLC decreased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 20.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 688,776 shares of the biopharmaceutical company’s stock after selling 173,242 shares during the quarter. Royalty Pharma accounts for approximately 3.6% of Torray Investment Partners LLC’s holdings, making the stock its 3rd biggest position. Torray Investment Partners LLC owned approximately 0.12% of Royalty Pharma worth $24,817,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. M&T Bank Corp increased its holdings in Royalty Pharma by 23.4% during the 1st quarter. M&T Bank Corp now owns 28,967 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 5,500 shares during the period. Nordea Investment Management AB increased its holdings in Royalty Pharma by 603.9% during the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock worth $23,701,000 after purchasing an additional 562,799 shares during the period. Amalgamated Bank increased its holdings in Royalty Pharma by 4.4% during the 1st quarter. Amalgamated Bank now owns 20,423 shares of the biopharmaceutical company’s stock worth $636,000 after purchasing an additional 866 shares during the period. Cookson Peirce & Co. Inc. increased its holdings in Royalty Pharma by 55.1% during the 2nd quarter. Cookson Peirce & Co. Inc. now owns 34,263 shares of the biopharmaceutical company’s stock worth $1,234,000 after purchasing an additional 12,171 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Royalty Pharma by 48.3% during the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 41,798 shares of the biopharmaceutical company’s stock worth $1,301,000 after purchasing an additional 13,615 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $37.54 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. The stock has a fifty day moving average of $36.19 and a two-hundred day moving average of $35.24. The company has a market capitalization of $21.89 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 2.06 and a beta of 0.56. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $38.00.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. The business had revenue of $578.67 million for the quarter, compared to analysts’ expectations of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. On average, analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 50.87%.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of research reports. Weiss Ratings downgraded Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Morgan Stanley cut their target price on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Citigroup increased their target price on Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. The Goldman Sachs Group started coverage on Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 target price for the company. Finally, Wall Street Zen raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus price target of $46.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.